Genetic Engineering of T-cells for Adoptive Immunotherapy of Chronic Lymphocytic Leukemia

用于慢性淋巴细胞白血病过继免疫治疗的 T 细胞基因工程

• 批准号: G0501935/1
• 负责人: Martin Pule
• 金额: $ 77.38万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2007
• 资助国家: 英国
• 起止时间: 2007 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0501935%2F1
• 关键词: Genetic; Engineering; cells; Adoptive; Immunotherapy

The immune system is highly effective at removing large-numbers of virally infected cells without damaging normal non-infected tissues, however it often remains unresponsive to cancer cells. In this project, we plan to modify T-cells, a key component of the immune system, so that they kill established cancers. We propose taking normal T-cells from patients with a form of cancer known as chronic lymphocytic leukaemia (CLL), and genetically engineer them in the laboratory so that they kill the leukaemia cells, with a view to ultimately giving them back to the patient as a treatment. This engineering exploits our detailed understanding of how the immune system works. In a sense we will use nature‘s toolkit to create a cancer killing immune response. We will test these T-cells in mice with human leukaemias, to establish safety and effectiveness of this new form of treatment. We plan to use the data amassed from this project to prepare the ground-work for a clinical study in patients with CLL that have failed standard treatment. This work represents the beginning of a new field of therapy, where T-cells can be engineered to specifically remove harmful cell populations without damaging healthy normal tissue

免疫系统在清除大量病毒感染细胞方面非常有效，而不会损害正常的未感染组织，但它通常对癌细胞没有反应。在这个项目中，我们计划改造T细胞，T细胞是免疫系统的关键组成部分，这样它们就可以杀死已确定的癌症。我们建议从一种名为慢性淋巴细胞性白血病(CLL)的癌症患者身上提取正常T细胞，并在实验室对其进行基因改造，使其杀死白血病细胞，以期最终将其返还给患者作为治疗。这项工程利用了我们对免疫系统如何工作的详细了解。在某种意义上，我们将使用大自然的工具包来创造一种杀死癌症的免疫反应。我们将在患有人类白血病的小鼠身上测试这些T细胞，以确定这种新形式治疗的安全性和有效性。我们计划使用从这个项目中收集的数据来为对标准治疗失败的慢性淋巴细胞性白血病患者进行临床研究做准备。这项工作代表了一个新的治疗领域的开始，在这个领域中，T细胞可以被改造成在不损害健康正常组织的情况下专门去除有害细胞群